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Abstract: Integrins are heterodimeric cell surface receptors composed of α and β subunits that control
adhesion, proliferation and gene expression. The integrin heterodimer binding to ligand reorganises
the cytoskeletal networks and triggers multiple signalling pathways that can cause changes in cell
cycle, proliferation, differentiation, survival and motility. In addition, integrins have been identified
as targets for many different diseases, including cancer. Integrin crosstalk is a mechanism by which a
change in the expression of a certain integrin subunit or the activation of an integrin heterodimer
may interfere with the expression and/or activation of other integrin subunit(s) in the very same cell.
Here, we review the evidence for integrin crosstalk in a range of cellular systems, with a particular
emphasis on cancer. We describe the molecular mechanisms of integrin crosstalk, the effects of cell
fate determination, and the contribution of crosstalk to therapeutic outcomes. Our intention is to
raise awareness of integrin crosstalk events such that the contribution of the phenomenon can be
taken into account when researching the biological or pathophysiological roles of integrins.
Keywords: integrin; integrin adhesion complexes; integrin crosstalk; integrin switching; cancer
1. Introduction
Integrins are a large family of ubiquitously expressed transmembrane glycoprotein receptors that
function as major sensors of the extracellular environment and regulate many aspects of cell behaviour.
The majority of integrins are involved in cell–extracellular-matrix (ECM) interactions, while some
of them participate in cell–cell interactions. Upon integrin ligand binding, signals are initiated that
reorganise the cytoskeletal networks (actin, microtubules and intermediate filaments) and regulate
survival, proliferation, migration and differentiation [1–6]. Structurally, integrins are heterodimers
and, in humans, 18 different α and eight β subunits have been identified, which give rise to 24
heterodimers (Figure 1). Different integrins bind different ECM proteins and/or cell surface molecules
that have a specific spatial and temporal distribution pattern in a given tissue. Every cell type in the
body possesses its own specific integrin profile, which is perturbed in different pathophysiological
conditions, especially in cancer [3,7–10]. Upon integrin binding and clustering, proteins are recruited
to their cytoplasmic tails to form multimolecular integrin adhesion complexes (IACs), the composition
of which has been termed the adhesome. Excellent reviews have been published describing integrin
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structure and function, as well as IAC composition [3–5,11–21]. These reviews also highlight the
versatility of integrin family and its contribution to different aspects of cell behaviour. Consequently,
the precise and dynamic regulation of the expression of a single integrin type has the potential to
directly affect cell signalling and fate.
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Figure 1. Pairing of integrin subunits. Integrins are transmembrane proteins that mediate cell 
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have been identified, which give rise to 24 heterodimers. Different integrins bind different ECM 
proteins and/or cell surface molecules, which have a specific spatial and temporal distribution pattern 
in a given tissue. Integrins are separated into subsets of closely related subunits. 
Functional and morphological analyses have defined several major forms of IACs, including 
nascent adhesions (NAs), focal adhesions (FAs), fibrillar adhesions (FBs) [16,22], hemidesmosomes 
(HDs) [21] and recently discovered reticular adhesions (RAs) [13]. NAs are small, transient structures, 
turning over in order of minutes, sampling the local ECM before disassembling or moving on to form 
more stable, mature FA structures which are strongly associated with actin filaments [12,23]. FBs are 
long, stable structures that run parallel to bundles of fibronectin in vivo and are highly enriched in 
tensin and α5β1 integrin [24,25]. HDs are multiprotein complexes that enable the stable adhesion of 
basal epithelial cells’ internal keratin intermediate filament network to the underlying basement 
membrane and have a different molecular composition from FAs and FBs [21]. Finally, RAs are new 
class of IACs that normally lack association with the cytoskeleton, are rich in components of the 
clathrin-mediated endocytosis machinery and are also termed clathrin-coated plaques, flat clathrin 
lattices, or clathrin sheets [13,26]. 
Schwartz and Ginsberg [27] defined the term ”crosstalk” between integrins or between integrins 
and growth factor receptors as ”unwanted signals in a communication channel caused by the transfer 
of energy from another circuit” that may lead to unpredictable and potentially deleterious biological 
responses. The same term integrin crosstalk was also used by Gonzales and colleagues [28] for a 
mechanism in which one integrin regulates the activation state of a different integrin in the same cell. 
They also utilised the term ”transdominant inhibition”, which has been used by other researchers 
[29,30]. Here, we review the evidence for the modulation of activation/expression of one integrin 
affecting the activation/expression of another integrin and we use the umbrella term of integrin 
crosstalk. Since blocking antibodies and inhibitors, as well as the manipulation of integrin subunit 
expression, either by overexpression, knockdown or knockout, is widely used in research and could 
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blocking antibodies and inhibitors, as well as the manipulation of integrin subunit expression, either
by overexpression, knockdown or knockout, is widely used in research and could potentially be
translated in vivo and into the clinic, our aim is to review integrin crosstalk events that may lead to
unpredictable biological responses. We collected integrin crosstalk data from many systems, and
we believe this overview provides a useful source of information for researchers that are interested
in integrin activation/expression in their experimental settings. It should be noted that most of the
data collected describe integrin crosstalk in cancer as this is the focus of our own research. We also
emphasize the potential clinical implications of this phenomenon.
2. Regulation of Integrin Expression
The individual integrinα orβ subunits are not expressed on the cell surface. Only those assembled
as heterodimers, the process which occurs in the endoplasmic reticulum (ER), are displayed on the
cell surface and are able to bind their ligands and trigger signalling [31]. Their transport from ER to
the plasma membrane is allowed only if they attain their native structure [32,33]. Ca2+ has a crucial
role in integrin folding, assembly and trafficking maintaining the receptors in an inactive form until
they reach the cell surface [34]. When expressed on the cell surface, integrin heterodimers can exist in
three different states (which equate to conformational classes): (i) an inactive form with low affinity for
ligand; (ii) a primed form with high affinity for ligand or (iii) a fully activated ligand-bound form [35,36].
Integrin activation is bidirectional. In “inside-out“ signalling, integrins are activated by conformational
changes due to the binding of talin and kindlin to the cytoplasmic tail of integrins [37,38]. Integrins
that bind with high affinity ligands trigger ”outside-in” signals [31,39]. The conformational changes
that accompany inside-out and outside-in signalling are very similar, emphasising the role of integrins
in relaying mechanochemical information between the cytoplasm and plasma membrane.
Because of their essential role in the cell, the expression of integrin heterodimers on the cell surface
is precisely and dynamically regulated on several levels by a multitude of mechanisms including: (i)
regulation of integrin protein levels by transcriptional or post-transcriptional mechanisms; (ii) alteration
of integrin protein primary sequence by alternative splicing of mRNA; (iii) mobilization to the cell
surface of pre-existing intracellular stores of integrins; and (iv) modulation of integrin internalisation
and recycling. Initially, it was shown that ECM controls the expression of integrin subunits and that
this regulation is exerted at both transcriptional and post-transcriptional levels [40]. Subsequently,
many signalling pathways and signalling molecules, such as growth factors, cytokines, hormones
and pharmacological agents, as well as microRNAs, have been shown to regulate integrin expression
in a myriad of cell types, both on mRNA and protein level [41–45]. Alternative splicing has been
found for mRNAs of several integrins during development and tumorigenesis and was shown to be
tissue-specific [41]. Although the expression of particular integrin subunits is regulated by different
mechanisms, it has been shown via knockin, knockdown and knockout experiments that the repertoire
of integrin heterodimers on the cell surface depends on the availability of bothα andβ integrin subunits
in the intracellular reservoirs. However, the heterodimeric nature of integrins, the fact that many
heterodimers share the same α or β subunits and the limited data on the regulation of expression of αβ
integrin heterodimers sharing the same α or β subunits makes the conclusion about the mechanisms
of the pairing hierarchy difficult. For example, it has been shown in WM-266-4 melanoma cells that
the number of αvβ3 and αvβ5 heterodimers on the cell surface depends on the level of expression
of β3 and β5 subunits, respectively, but the expression of the αv gene dictates the number of αvβ1
heterodimers [46]. Similarly, in human lung fibroblasts WI-38 β1 subunit is made in excess over α
subunits, and assembly of β1 subunits with rate-limiting α subunits is required for expression of
αβ1 on the cell surface [47]. Finally, integrin expression can be regulated by modulation of integrin
internalisation and recycling, which has been shown to contribute to the dynamic remodelling of
adhesion [48].
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3. The Integrin Repertoire Is Changed or ”Switched” in Cancer Cells—an Indication of Integrin
Crosstalk Events
Given the essential role of integrins in several key cell behaviours and processes, like migration,
adhesion, proliferation, survival, differentation, positioning, metabolism, matrix assembly, gene
expression and receptor tyrosine kinase signalling, it is no surprise that integrins represent important
players during cancer initiation, progression and metastasis [2,5,49–54]. Several other important cancer
traits, like stemness and drug resistance, as well as the control of tumor microenviroment, have also
been shown to be regulated by integrins [2,5,7,17,50,55,56].
Oncogenic transformation, directly or indirectly, changes the repertoire of integrins on the surface
of a cancer cell. Virtually, the integrin repertoire is ”switched” to support cancer initiation and
progression [17,57]. In order to avoid confusion, here we use the term ”integrin switching” as a term
for integrin repertoire change on the cell surface, which may or may not be due to ”integrin crosstalk”.
As we already emphasized, the transcription of integrin subunits does not determine the
repertoire of integrin heterodimers on the cell surface but can serve as an indication of the integrin
“switch“. Therefore, we analyzed the expression of integrin subunits across different cancer types
and corresponding normal tissues using the TCGA (https://www.cancer.gov/) and GTEx databases
(https://www.gtexportal.org/) using GEPIA software [58]. As shown in Figure 2, mRNA expression
of integrin subunits is highly perturbed in different cancer types. In glioblastoma and pancreatic
adenocarcinoma, the upregulation of almost all integrin subunits is observed. Conversely, in sarcoma,
only the downregulation of integrin β6 is found. The shade of grey in Figure 2 indicates the level
of expression of a particular integrin subunit, showing that integrin subunits α3, α5, α6, αv, β1, β4
and β5 are the most highly expressed. The combination of these integrin subunits give rise to the
integrin heterodimers α3β1, αvβ1, αvβ5, α5β1 and α6β4 shown to be involved in formation of FAs
(α3β1, αvβ1, αvβ5), FBs (α5β1) [12,25]. They are also highly altered in 31 cancer tissues analysed here
compared to normal ones. Integrins β1 and β5 were found to be exclusively upregulated, in 11 and
nine cancers, respectively. Integrin αv was upregulated in nine and downregulated only in two cancer
types, while integrin α3 was found to be upregulated in 12 and downegulated in five. The integrin
α5 which is the only one forming FBs is found to be more frequently downregulated (in 12 tumours)
than upregulated (in six). However, the most pronounced changes were observed for integrin subunit
α6 that was upregulated in 18 and downregulated in three, and β4 that was upregulated in 15 and
downregulated in three cancer types, respectively. These particular integrin subunits heterodimerise
into α6β4 which form HDs [21]. Therefore, the changes observed are expected, since most of the
cancer types analysed in Figure 2 are carcinomas developed from epithelial tissues for which the
importance of hemidesmosome components in carcinogenesis was recently reviewed [59]. Moreover,
recently published data by Wang and colleagues [14] revealed a novel role for HDs as regulators of
cellular mechanical forces. They showed the existence of a mechanical coupling between different
IACs, specifically HDs and FAs and RAs.
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Figure 2. Integrin expression in different tumor (T) and corresponding nor al (N) tissues. Statistically
significant changes are marked with a rectangle (log2 fold change > 1, p-value 0.01). Figure is made
using GEPIA software (http://gepia.cancer-pku.cn/) [58]. r i ti ns and number (in parenthesis)
of tumor and normal sa l analysed (combined TCGA and GTEx), respectively. Tumors are
listed in an alphabetical order: ACC, adren cortical carcinoma (77, 128); BLCA, bla der urothelial
car inoma (40 , 28); BRCA, breast invasive carcino a (10 , cervical squamous cell
car inoma and endocervical adenocarcinoma (306, 13); l giocarcinoma (36, 9); COAD,
colon adenocarcinoma (275, 349); DLBC, diffuse large B-cell l ( 7, 337); ESCA, esophageal
carcinoma (182, 286); GBM, glioblastoma multiforme (163, 2 ); , ad and neck squamous cell
carcinoma (519, 44); KICH, kidney chromophobe (66, 53); I , kidney renal clear cell carcinoma
(523, 100); KIRP, kidney renal papillary cell carcinoma (286, 60); LAML, acute myeloid leukemia
(173, 70); LGG, lower grade glioma (518, 207); LIHC, liver hepatocellular carcinoma (369, 160); LUAD,
lung adenocarcinoma (483, 347); LUSC, lung squamous cell carcinoma (486, 338); OV, ovarian serous
cystadenocarcinoma (426, 88); PAAD, pancreatic adenocarcinoma (179, 171); PCPG, pheochromocytoma
and paraganglioma (182, 3); PRAD, prostate adenocarcinoma (492, 152); READ, rectum adenocarcinoma
(92, 318); SARC, sarcoma (262, 2); SKCM, skin cutaneous melanoma (461, 558); STAD, stomach
adenocarcinoma (408, 211); TGCT, testicular germ cell tumors (137, 165); THCA, thyroid carcinoma
(512, 337); THYM thymoma (118, 339); UCEC, uterine corpus endometrial carcinoma (174, 91); UCS,
uterine carcinosarcoma (57, 78).
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As we emphasized before, integrins must form heterodimers in order to be expressed on the cell
surface and, therefore, the expression of integrin transcripts is not a firm indication of the protein
expression on the cell surface. In accordance with this, discrepancies between the expression of integrin
subunit mRNA and protein in particular cancer tissues have been found. For example, mRNAs of
integrin subunits α5, α7, β3, β6 and β8 are underexpressed in prostate cancer tissue in comparison to
normal (Figure 2), while the immunohistochemistry data suggest their overexpression [60]. One of the
possible explanations for this might be that immunohistochemistry data does not discriminate between
integrins expressed on the cell surface as heterodimers from integrin subunits in the intracellular stores.
An example of how expression of integrin subunit transcripts altered in tumors does not correlate
with their involvement in the biology of particular cancer can be found in melanoma. Namely, the
expression of integrin subunits β1, β3 and α4 is increased while expression of α2, α5, α8, β4 and β6
is decreased as compared to normal tissue (Figure 2). However, increased expression of integrins
α5β1 and αvβ3 results in a poor melanoma prognosis, increased cell invasion, and metastasis [61,62],
while data obtained in vitro in different melanoma cell lines showed that integrin αvβ5 is involved in
the higly aggressive phenotype of cells expressing neuropilin 1 [63], and is involved in sensitivity to
microtubule poison paclitaxel and increased in vitro migration and invasion [64,65].
4. Integrin Crosstalk
A common response of a cancer cell to anticancer treatment is the activation of diverse
compensatory mechanisms (reviewed in [66–68]) that are elicited to circumvent the inhibition of
a targeted signalling pathway. This kind of plasticity and the ability of the cell to rewire its signalling
pathways and internal processess is very often seen in other pathophysiological conditions like
nervous system diseases [69] or with host defense pathways [70]. Compensation is based on pathway
redundancy, feedback and crosstalk mechanisms [66]. Besides the redundancy in ligand affinity, the
integrin family possesses another innate characteristic similar to the cell compensation mechanisms
in the way that a change in the expression of integrin subunits or the activation of a certain integrin
heterodimer can interfere with the expression or the activation of the other. This phenomenon, that
we defined as integrin crosstalk, was described for the first time in 1994 in K562 erythroleukemia
cells in which de novo expression of αvβ3 led to the inhibition of α5β1 activitation and, consequently,
the inhibition of α5β1-mediated phagocytosis [71].
Integrin crosstalk has been mostly observed in experiments in vitro in cultured cells of different
origin performed in order to show a causal relationship between one integrin heterodimer and either
cell adhesion, migration, invasion, phagocytosis, size of particular focal adhesions or transduction
efficacy of adenovirus type 5 which uses RGD-binding integrins for internalisation. Interventions in
these experiments include integrin subunit overexpression or knockdown, cell exposure to blocking
monoclonal antibodies (MoAbs) to prevent integrin signalling or immobilised MoAbs for integrin
activation, use of specific integrin inhibitors, seeding cells on specific integrin binding substrates or the
introduction of inactive or constitutive active integrin mutants into cells. Table 1 describes integrin
crosstalk events collected from the literature.
A comprehensive analysis of integrin crosstalk in a particular cell model has never been done.
Similarly, reviewing the observed events does not indicate the type or frequency of the integrin crosstalk
phenomenon. However, by examining Table 1 we can conclude that some integrins are associated in
more than one cell type. An apparent inversely proportional relationship in mesenchymal stem cells is
found for integrins α1 and α2 [72]. Similarly, de novo expression of integrin α3 decreases the activation
of αv while α3 blocking antibody activates integrin αvβ3 in several cancer cell types [73]. Integrin
crosstalk between integrins α4β1 and αLβ2 has been observed in T cells by several research groups.
To be specific, de novo expression, the activation or crosslinking of α4β1 leads to activation of αLβ2
and increased migration as a consequence of adhesion of both integrins [74–76]. Blocking integrin α4
in oral squamous carcinoma cell line HSC-3 leads to upregulation, while integrin α4 expression leads
to the downregulation of both integrins α5 and αv, respectively. The exposure of cells to blocking Abs
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directed against either integrins α5 or αv, increases α4 and αv or α4 and α5, respectively, indicating
that these three integrin α subunits are mutually regulated in a crosstalk fashion [77]. A crosstalk
between integrins α5β1 and αvβ3 has been shown in endothelial cells [78,79], glioblastoma U-251MG
cells [80], chick chorioallantoic membrane cells (CAMs) [78] and chinese hamster ovary (CHO-B3)
cells [81]. In general, integrin α5β1 activation by either binding to a specific substrate or α5β1-specific
immobilised MoAb, respectively, increases αvβ3 activation [79,80]. Similarly, the inhibition of α5β1
signalling by an α5β1-blocking MoAb decreases αvβ3 activation [78]. The only exception to the αvβ3
dependency by α5β1 has been shown in CHO cells in which de novo expression of α5 decreases αvβ3
activation [81]. Conversely, when integrin αvβ3 was modulated or even depleted in different cell
models, the differential effect on α5β1 was observed [71,82–84].
The example of integrin crosstalk, which is of outstanding importance to the clinic is the one
between different integrin β1 heterodimers and αvβ3. The knockdown of β1 in different human and
mouse breast cancer cell lines or kidney cells leads to αvβ3 activation. However, the outcome of these
integrin crosstalk events is differential, either increased or decreased metastasis [85–89], indicating that
it is very likely that the overall impact on metastasis depends on the strength of the crosstalk between
the two integrins.
Integrin crosstalk is very likely dependent on the repertoire of integrins expressed on the cell and
the amount of integrins in intracellular stores. A very simple compensation crosstalk mechanism was
observed in melanoma cell line MDA-MB-435S, which preferentially expresses integrins β3 and β5 as
αv integrin subunit-binding partners. In this cell line, the knockdown of either subunit β3 or β5 not
only downregulates the expression of αvβ3 or αvβ5 but simultaneously upregulates αvβ5 or αvβ3,
respectively, maintaining the expression of the similar amount of total integrins αv (both αvβ3 and
αvβ5) on the cell surface, representing a certain ”balance” effect. However, a simillar effect was not
observed in melanoma RPMI-7951 and breast carcinoma MDA-MB-231 cell lines [64]. Other examples
of integrin crosstalk between αv integrins [64,90–92] will be discussed in the section dedicated to
integrin crosstalk mechanisms.
Table 1 describes additional integrin crosstalk events observed upon manipulation of integrin
subunits or heterodimers in different cell lines. We summarised the integrin crosstalk examples in
Figure 3 to show frequency and type of integrin crosstalk derived from the manipulation of either
subunits α (Figure 3a), β (Figure 3b) or integrin heterodimers αβ (Figure 3c).
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Table 1. Integrin crosstalk examples found in different research models. The table describes only integrin crosstalk events and corresponding outcome.
Cells Intervention Integrin Crosstalk Outcome Reference
MSC
lentivirus expressing α1 shRNA ↑ α2, α11 mRNA andprotein expression changes in cell adhesion andmigration were not ascribed to
changes in individual integrins
α2 or α11 knockdown resulted
in cell death
[72]lentivirus expressing α2 shRNA ↑ α1, α11 mRNA andprotein expression
lentivirus expressing α11 shRNA ↑ α1 mRNA and protein expression
MDA-MB-231 α3-blocking Ab ↑ α2β1 activation ↑ adhesion to COL [93]
B10-renal cells from E18
α3-defficient mouse
de novo expression of human α3
subunit ↓ activation of αv
↓ cell adhesion to the α3
noncollagenous (NC1) domain
of COL IV
[73]
A549, HT144, HUVEC α3-blocking Ab ↑ αvβ3 activation
↑ adhesion to the α3
noncollagenous (NC1) domain
of COL IV
Wi26
microinjection of the α3 peptide
representing the cytoplasmic domain
of the α3 integrin
disengagement of the α6β1 reduced size of α6β1-focaladhesions [94]
primary human skin fibroblasts α3β1-function blocking Ab ↓ α6β1 integrin clustering reduced size of α6β1-focaladhesions [95]
CHO stable transfection of murine α4cDNA ↑maturation of β1 precursor [96]
Jurkat α4-defficient cells de novo expression of α4 ↑ αLβ2 activation
↑migration that was
αLβ2-dependent and
VCAM-dependent
[75]
lymphocytes isolated from
α4(S988A) bearing mice
↑ α4 activation (S988A) which
precludes PKA-mediated α4
phosphorylation
↑ αLβ2 activation
↑migration on ICAM-1
↑ homing to B16 melanoma
in vivo
[76]
Jurkat crosslinking of α4β1 clustering αLβ2 ↑ adhesion to ICAM-1 [74]
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Table 1. Cont.
Cells Intervention Integrin Crosstalk Outcome Reference
human T-cells
inhibition of α4β1 with blocking
MoAb
α5β1 activation or expression was
not analysed ↑migration mediated by α5β1
[97]
interaction of the αLβ2 with its ligand
ICAM-1 or αLβ2-activation Ab
↓ binding of α4β1 and to a lesser
extent α5β1
↓ adhesion mediated by α4β1 to
FN and VCAM-1 and, to a lesser
extent, α5β1 to FN
HSC-3
α4-blocking Ab ↑ α5 and αv ↑ in vitro migration
[77]
overexpression of α4 using transient
transfection with plasmid containing
α4 gene
↓ α5 and αv ↓ in vitro migration
α5-blocking Ab ↑ αv and α4 = in vitro migration
αv-blocking Ab ↑ α5 and α4 = in vitro migration
CHO-B3 (negative for α5β1 and
positive for αvβ3)
de novo expression of α5 using stable
transfection with plasmid coding for
α5 gene
↓ αvβ3 activation
↓ adhesion to FBG and
αvβ3-mediated migration
on FBG
[81]
U-251MG ligation of α5β1 by plating cells onimmobilised α5 MoAb ↑ αvβ3 activation
↑ αvβ3-mediated
internalisation of VN [80]
HUVEC α5β1-blocking Ab and smallmolecule antagonists of α5β1 ↓ αvβ3 activation
↓ formation of αvβ3 focal
adhesions
↓ αvβ3-mediated in vitro
migration on VN
[78]
chick CAM α5β1-blocking Ab ↓ αvβ3 activation ↓ angiogenesis in vivo
primary HUVEC seeding to α5β1 selective substrate ↑ αvβ3 recruitment ↑ cell spreading [79]
immortalized epidermal
keratinocytes
lentivirus containing
α6-specific shRNA
↓ α3 and α2 mRNA transcription and
translation
↓ surface expression of α3β1 and
α2β1
↓adhesion to LN332 and COL
↓migration [98]
α9β1 null mice keratinocyte
cell line
de novo expression of α9β1 using a
retrovirus containing human α9 gene ↓ α3β1 activation
↓ α3β1-mediated migration
in vitro on LN-332 [99]
CHO
αIIbβ3-specific inhibitor
(ligand Ro43-5054)
↓ adhesive function of α5β1 ↓ adhesion to FN
[29]↓ adhesive function of α2β1 ↓ adhesion to COL
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Table 1. Cont.
Cells Intervention Integrin Crosstalk Outcome Reference
HT29-D4
reduction of αv expression that is
targeted to and degraded in
lysosomes (reduces αvβ5/β6
expression)
↑ α2β1 activation ↑ cell migration [100]
pKO, pan-ITG deficient murine
fibroblasts reconstituted with
αv and β1
binding to FN fragment FNIII7-10
(contains the RGD- and
PHSRN-motifs)
αv integrins engagement activates
α5β1 to establish additional adhesion
sites to FN
↑ formation of α5β1 mediated
adhesion clusters, adhesion
strenghthening
[84]
HEK293 (β3wt)
HUVEC
MG-63
αvβ3-blocking Ab and αvβ3 ligand
cyclic G-Pen-GRGDSPC-A (small
peptide antagonist)
↓ α5β1 signallig
↓ α5β1-mediated migration
toward FN, but not attachment
to FN
[82]
K562
de novo expression of αvβ3 using
stable transfection with plasmid
coding for β3 gene
↓ α5β1 activation ↓ α5β1-mediated phagocytosis [71]
TrHBMEC
and HUVEC
αvβ3-blocking Ab ↓ α3β1 and α6β1 adhesion ↓ adhesion to LM5 and α4 LMG domain
[101]
β1-blocking Ab ↓ αvβ3 adhesion ↓ adhesion to α4 LM G domain
α3 and α6-blocking Ab ↓ αvβ3 adhesion ↓ adhesion to α4 LM G domain
MG-63 αvβ5-blocking Ab or cyclic peptideRGDfV ↑ α5β1 activation unknown [102]
CHO-B2
HeLa
deletion of α5β1 N-glycosylation
site-11 that inhibits EGFR binding ↑ α6β4-EGFR complex ↑ cell proliferation [103]
MG-63
knockdown of β1 using stable
transfection with plasmid coding for
shβ1 RNA
↓ protein maturation of α3 and α5
↑ protein maturation of β1 =expression of surface β1 [104]
4T1
knockdown of β1 using stable
transfection with plasmid coding for
shβ1 RNA
↑ β3 mRNA
↓ in vivo tumor growth and ↑
in vivo metastasis which is not
due to compensatory
β3 expression
[88]
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Table 1. Cont.
Cells Intervention Integrin Crosstalk Outcome Reference
4T1 and MDA-MB-231
knockdown of β1 using stable
transfection with plasmid coding for
shβ1 RNA or exposure to
β1-blocking Ab
↑ β3 mRNA and protein expression
↑ acinar cell growth, = growth
of 3D organotypic culture and =
in vivo metastasis due to
compensatory β3 expression
[87]
HKC
knockdown of β1 using stable
transfection with plasmid coding for
shβ1 RNA
↑ αvβ3 activation
↑ αvβ3 localization to FA
↑ TGF-β1 induced COL mRNA
expression
[85]
MMTV-NIC mice mammary-specific deletion of β1 inthe NIC model
↑ β3 mRNA and αvβ3 expression on
the cell surface
modest delay of tumor onset
and a significant inhibition of
lung metastasis
[89]
MMTV-NIC mice mammary-specific deletion of β1 inthe NIC model
↓ β4; ↑ α5, αv, β3, β5 total protein
levels measured by western blot
modest delay of tumor onset
and a significant inhibition of
lung metastasis
[86]
TrHBMEC β1-blocking Ab ↓ αvβ3 activation ↓adhesion to a recombinant LMfragment and VN [105]
GD25 (β1-null)
stable de novo expression of β1B
isoform using stable transfection with
plasmid coding for β1B gene
↓ αv adhesion
↓ αv containing focal adhesions
and actin stress fibers
↓ spreading to FN
(mediated by αvβ3)
[106]
GE11 β1-null de novo expression of β1 ↑ surface αvβ5 unknown [107]
GD25 β1-null de novo expression of the β1A or B
↓ β3 mRNA stability; ↓ surface αvβ3
↑ surface αvβ5 (translational and
post-translational level)
= surface αv
unknown [108]
PMN
β2-cross-linking Ab ↑ expression of β1 integrins on thecell surface
↑ adhesion to FN (through α5β1
and lesser extent α4β1) and
COL (through α2β1) [109]
adhesion to COL gel
(involvement of β2)
↑ expression of β1 integrins on the
cell surface ↑ α2β1-dependent migration
Jurkat activation of β2 through the T-cellreceptor or chemokines ↓ activation of α4β1
↑ in vitro migration
↓ binding to VCAM-1 [110]
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Table 1. Cont.
Cells Intervention Integrin Crosstalk Outcome Reference
MDA-MB-435S transfection with β3 or
β5-specific siRNA
↑ surface expression of αvβ5 or αvβ3,
respectively, = surface expression
of αv
= in vitro migration
(unlike knockdown of αv which
↓migration)
[64]
Cal27
de novo expression of β3 using stable
transfection with plasmid coding for
β3 gene
↑ β5 mRNA
↑ surface expression of αvβ5 unknown [92]
HEp2
de novo expression of β3 using stable
transfection with plasmid coding for
β3 gene
↓ αvβ5 on the cell surface ↓ Adenovirus type 5transduction efficacy [90,91]
NIH3T3
deficient mutants β3Y759A and β31-760
that cannot bind protein kinase
D1 (PKD1)
↑ α5β1 recycling and signalling
↓ peristent and directional
migration
↑ random migration
[83]
immortalised fibroblasts from
β3-null mice vs. WT fibroblasts depletion of β3 ↑ β1 activation
↓ peristent and
directional migration
↑adhesion dynamics
↑migration speed
[111]
CHO
de novo expression of Tac-β3
constructs with impaired talin
binding activity in αIIbβ3
↓ α5β1 activation ↓spreading on FBG [112]
SW480
de novo expression of β6 using stable
transfection with plasmid coding for
β6 gene
↓ α2, α6, β1, β4 and β5 protein
expression detected by mass
spectrometry
↓ adhesion through β2, β3
and β4
↓ adhesion to COL I and II,
FN and VN
↑ in vitro invasion
[113]
↑, increase in the expression, or increase in the process stated; ↓, decrease in the expression, or the decrease in the process stated; =, no difference; FN, fibronectin; VN, vitronectin, COL,
collagen; LM, laminin; FBG, fibrinogen; si, knockdown via small interefering RNA; sh, knockdown via shorth hairpin RNA; MMP, matrix metaloproteinase; KO, knockout; MoAb,
monoclonal antibody; Ab, antibody. Cells: 4T1, mouse breast carcinoma; A549, lung carcinoma cells; Cal27, tongue squamous cell carcinoma; CAM, chorioallantoic membrane; CHO,
chinese hamster ovary; GD25, mouse embryonic fibroblast cell line; GE11, β1-defficient epitheloid cells isolated from β1 chimeric embryos; HEK-293, embryonic kidney; HeLa, cervix
adenocarcinoma; HEp2, laryngeal carcinoma; HKC, human renal tubular epithelial cell line; HSC-3, oral squamous cell carcinoma; HT-144, melanoma; HT29-D4, colon cancer; HUVEC,
human umbilical vein endothelial cells; Jurkat, T cell lymphoma; K562, erythroleukemia; MDA-MB-231, triple negative breast carcinoma; MDA-MB-435S, melanoma; MG-63, osteosarcoma;
MMTV-NIC mice, mouse mammary tumor virus activated erbB2 with an internal ribosome entry site driving expression of the Cre recombinase under the transcriptional control of the
MMTV promoter; MSC, mesenchymal stem cells; NIH3T3, mouse fibroblasts; PMN, polymorphonuclear leukocytes; SW480, colorectal adenocarcinoma; TrHBMEC, immortalized human
bone marrow endothelial cells; U-251MG, glioblastoma; Wi26, lung fibroblast line.
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Figure 3. Integrin crosstalk examples documented in experiments that interfere with (a) α or (b) β integrin subunit or (c) integrin heterodimer, listed in Table 1. ↑ 
denotes upregulation of integrin expression or activation, while ↓ denotes integrin downregulation or inhibition. 
Figure 3. Integrin crosstalk examples documented in experiments that interfere with (a) α or (b) β integrin subunit or (c) integrin heterodimer, listed in Table 1.
↑ denotes upregulation of integrin expression or activation, while ↓ denotes integrin downregulation or inhibition.
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5. Molecular Mechanisms of Integrin Crosstalk
Mechanisms that trigger integrin crosstalk are diverse and act on several levels of integrin
(bio)chemistry (Figure 4). In subsequent sections, we describe the integrin crosstalk mechanisms using
examples from the literature.
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Figure 4. Integrin crosstalk mechanisms. The mechanisms act on several levels: on the level of changes
in stoichiometry of integrin subunits, transcription, but also on the level of changes of integrin proteins
(maturation, post-translational modifications, transport and recycling) and the activation of an integrin.
Integrin crosstalk mechanisms are in lower case.
5.1. Changes in Stoichiometry of Integrin Subunits
As we already emphasized, only integrins assembled as heterodimers are displayed on the cell
surface. This process occurs in the ER [31]. Factors affecting the type of heterodimer to be formed are
also the propensity of integrin subunits to form certain integrin heterodimers, the relative affinities of
integrin subunits for heterodimerization a d stoichiometry. Integrin crosstalk is often doc e te in
knockd wn and overexpression experim nts where the expression of i tegrin heterodimers is altered
by the availibility of integrin subunits. As mentioned i a prev ous section, in human melanoma
cells MDA-MB-435S, knockdown of integrin β3 subunit decreased the amount f integrin αvβ3,
but simultaneously upregulated integrin αvβ5, and vice versa. The increased expr ssion of αvβ5
could be a consequence of the liberated amount of integri αv (upon β3 knockd wn) and the excess
amount of integrin β5 subunit being able to form αvβ5 and vice versa [64]. These results are in
line with results obtained by Koistinen and Heino [46], where they show that the number of αvβ3
and αvβ5 heterodimers on the cell surface depends on the level of the expression of β3 and β5
subunits. We documented a similar mechanism in human laryngeal carcinoma HEp2 cell clones stably
transfected with a plasmid coding for integrin subunit β3 that led to de novo αvβ3 expression but,
in turn, downregulated integrin heterodimer αvβ5. Namely, integrin β3 competed with β5 for the
available integrin subunit αv in the cell, which resulted in decreased expression of αvβ5 [90,91].
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5.2. Effects on Transcription
Integrins affect gene expression through numerous mechanisms (crosstalk with catalytically
active transmembrane receptors; association with signal transducers; or cytoskeletal-dependent
mechanotransduction) and, in some cells, this regulation plays an important role in differentiation,
proliferation and other processess in the cell [114]. Among a repertoire of different genes whose
expression is affected by integrins are integrins themselves. The effect on transcription was observed
in human tongue squamous carcinoma cells Cal27 in which de novo expression of integrin subunit
β3, that led to de novo expression of integrin αvβ3 heterodimer, increased the expression of integrin
subunit β5-specific mRNA and integrin heterodimer αvβ5 expression on the cell surface, without
transcriptional upregulation of integrin subnit αv [92]. Knockdown of α1, α2 or α11-specific mRNA in
human mesenchymal stem cells was shown to upregulate transcription of α2 and α11, α1 and α11 or
α1 mRNA, respectively but only α2 or α11 knockdown, preventing interaction with collagen type I,
resulted in cell death [72]. Knockdown of α6 mRNA in human keratinocytes decreased transcription
of both, α3 and α2 integrin mRNAs [98]. In several papers, using knockdown of integrin β1 in breast
carcinoma cells or in vivo mouse model of mammary-specific deletion of β1, the increased expression of
mRNA specific for β3 was observed [86–89]. The integrin crosstalk through effects on transcription was
also observed in renal cells upon integrin β1 knockdown which increased transcription of β3-specific
mRNA [85] and in mouse embryonic fibroblast GD25 cell line in which de novo expression of the β1A
and β1B decreased the β3 mRNA stability [108].
5.3. Effects on Integrin Maturation
The production of functional proteins from translated polypeptides includes enzymatic processing,
folding and assembly into oligomeric complexes [115]. The integrin maturation process is shown to
be regulated by different molecules like alkaline ceramidase 2 [116], presenilins [117] or low-density
lipoprotein receptor-related protein-1 [118]. Integrin crosstalk has been shown at the level of β1
integrin subunit maturation. Koivisto et al. [104] showed that depletion of the pre-β1 integrin subunit
pools in ER (during malignant transformation, for example), accelerates the maturation rate of the
pre-β1 integrin subunit, which slows down the maturation of the α3 and α5 subunits. Similary, Jaspers
and colleagues [96] showed that introducing α4 cDNA and overexpressing this subunit in CHO cells
increased the rate of maturation of the β1 precursor and the quantity of β1 integrin on the cell surface.
5.4. Changes in Integrin Post-translational Modifications
Post-translational modifications of proteins are diverse and greatly influence protein function
and turnover. Recently, it has been shown that N-glycosylation of Asn712 on α5β1 integrin controls
the EGFR complex formation with integrin α5β1 or α6β4. The loss of this glycosylation site switched
the formation of EGFR-α5β1 complex to EGFR-α6β4, which is known to promote cell growth [103].
Retta and colleaugues [108] observed in mouse embryonic fibroblast GD25 cell line that the de novo
expression of β1 integrin increased the expression of integrin heterodimer αvβ5 through translational
and post-translational effects.
5.5. Changes in Transport and Recycling
The endocytic and exocytic trafficking of integrin receptors is an important mechanism regulating
their expression on the cell surface and processess they are involved in (reviewed in [48,119]).
White et al. [83] showed that recycling of αvβ3 during fibroblast migration antagonizes α5β1 recycling
which regulates the balance between persistent and random migration. Interestingly, both active and
inactive integrins can be recycled [120].
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5.6. Competition for Intracellular Activators
Talin is a key regulator of integrin activation [121], and it is not surprising that is an important
factor in integrin crosstalk. The example of such a regulation was described in 2004 by Calderwood
and colleagues [112] who showed that β3 inhibited the activation of α5β1 through competition with
talin, while Gonzalez et al. [105] showed that the β1 integrin subunit negatively modulates αvβ3
integrin–ligand binding via protein kinase A (PKA) and inhibition of protein phosphatase 1 (PP1)
activity. The calcium/calmodulin-dependent protein kinase II (CaMKII) is another protein found to
be involved in integrin crosstalk, which is activated by integrin α5β1. Ligation of the integrin αvβ3
prevented activation of CaMKII by α5β1, inhibited both phagocytosis and migration mediated by
α5β1. The β3 cytoplasmic tail was also found to be necessary and sufficient for this regulation [122].
6. Is Integrin Crosstalk One of the Reasons for Integrin Targeting Therapy Failure?
Overexpressed integrins are potential drug and imaging targets. They are implicated in almost
every step of cancer development and metastasis and, therefore, represent attractive targets for anticancer
treatment. The literature on the cancer-promoting role of integrins is extensive and there are several cancer
types in which integrin-targeting molecules, such as antibodies or integrin antagonists or inhibitors,
have been tested in different clinical trial phases (for reviews, see [2,8,9,17,56,123]. Integrin signalling
confers either primary or adaptive resistance of cancer cells to chemotherapy and radiotherapy [7,18,124]
which are still the treatments of choice for many solid tumors. Therefore, different integrins remain
interesting targets for the sensitization of tumor cells, or even cancer stem cells to chemotherapy
and radiotherapy, but also inhibit metastasis, as it has been shown for breast carcinoma [64,125,126],
head and neck squamous cell carcinoma [127], glioblastoma [128,129], melanoma [65,130], prostate
cancer [131], ovarian cancer [132], lung cancer [133] and many others. Recent data have shown
that integrin signalling confers resistance to targeted agents like vemurafenib [134] or lapatinib and
trastuzumab [135]. Finally, not only integrins expressed on tumor cells, but also integrins expressed
on cancer-associated fibroblasts (CAFs), namely α11β1, a receptor for fibrillar collagen during the
differentiation of fibroblasts into CAFs, have an important role in the promotion of tumor growth
and metastatic potential of non-small cell lung carcinoma cells. Specifically, the growth of A549 lung
adenocarcinoma xenografts in integrin α11 knockout (−/−) mice was significantly impeded [136].
Therefore, integrins are potential targets for the enhancement of targeted therapy. Targeting integrins
may be achieved with MoAbs, integrin antagonists and inhibitors, but also using RNA interference
mechanism upon transfection with integrin specific small interfering RNA (siRNA). However, many
factors prevent the development of integrin-based therapeutics for cancer. An important factor might
be integrin crosstalk. Therefore, a deeper understanding of the mechanisms of integrin crosstalk may
lead to the development of better integrin-based therapies or the development of integrin-related
biomarkers that predict the success of therapy.
The clinical significance of integrin crosstalk is exemplified by the work from Dallari et al. [137] who
showed that a changed number of available integrin subunits can be achieved by an integrin antagonist.
They used natalizumab, a MoAb directed against integrin α4 in multiple sclerosis patients and reported
upregulation of integrins α4 and β2 on monocyte subsets in the peripheral compartment. This is a clear
example of how interfering with integrin expression/activation in patients can lead to integrin crosstalk.
In one of the initial papers on integrin crosstalk, Blystone and colleagues [71] suggested caution in
interpretation of the role of a particular integrin due to the fact that interfering with one subunit, or a
heterodimer, could influence the expression or function of others. In accordance with this early notion,
the relevance of integrin crosstalk in cancer therapy has become more recognized. The examples of
integrin crosstalk found in the literature and summarised here, most of which were detected in tumor
cells, either in vitro or in vivo, illustrates how targeting one integrin can have unwanted effects, like an
increase in metastatic potential mediated by other integrin whose expression/activation is changed. A
striking example of such an interplay has been demonstrated in an in vivo breast cancer mouse model
in which β1 knockdown or exposure to β1-specific blocking antibody induces the expression of β3
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leading to enhanced metastasis [88] or increased acinar cell growth and unchanged metastasts due to
the β3 compensation [87].
7. Conclusions
Regarding the essential role of integrins in many cellular processes and their ability to direct the
cell fate, it is of utmost importance that the mechanisms of their crosstalk are understood in detail.
Since integrins are recognized targets in cancer treatment, integrin crosstalk needs to be taken into
account and carefully analyzed in cancer cell models in vitro and in vivo to avoid unwanted effects.
The question arises as to whether some of the integrin targeting agents in the clinics are failing, at
least partly, because of the integrin crosstalk effect. This short review is our attempt to encourage
researchers in the integrin field to pay attention to integrin crosstalk events with an ultimate aim of
understanding its underlying mechanisms, cell biological significance, and potential implications for
therapy and diagnosis.
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ECM cell-extracellular matrix
IACs integrin adhesion complexes
NAs nascent adhesions
FAs focal adhesions
FBs fibrillar adhesions
RAs reticular adhesions
HDs hemidesmosomes
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